ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
19 announcements
3B BlackBio Dx sent a Reg 36(1)(b) letter to shareholders providing the weblink to its FY 2025-26 Annual Report ahead of the 54th AGM. No financial figures or business events are disclosed.
3B BlackBio Dx Ltd filed its FY 2025-26 Annual Report with BSE under Regulation 34(1). The report recaps its molecular diagnostics growth and global expansion.
3B BlackBio Dx Ltd issued notice for its 54th AGM on 29 September 2026. Proposed business includes FY26 financials adoption and Rs.5 per share final dividend.
3B Blackbio Dx Limited has appointed M/s. Sanjay Kasliwal & Associates as the Cost Auditor for the company.
3B BlackBio Dx reported Q1FY27 consolidated revenue of ₹33.49 Cr, up 50% YoY, driven by the Coris BioConcept acquisition. Core MDx business grew 17.4% excluding Coris.
3B BlackBio Dx Ltd reported revenue from operations of ₹33.5 Cr (+50.9% YoY) and net profit of ₹9 Cr (-28.6% YoY) for Q1 FY27.
3B BlackBio Dx Ltd has scheduled a board meeting for August 13, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.
Promoter Dhirendra Dubey bought 1,000 shares of 3B BlackBio Dx Ltd via open market on June 24, 2026. His stake rose from 8.44% to 8.45%, a 0.01% increase.
3B BlackBio reported FY26 consolidated revenue of ₹142 cr and PAT of ₹60 cr, driven by diagnostic growth and contributions from Coris BioConcept and TRUPCR Europe.
3B BlackBio reported strong FY26 consolidated revenue of ₹142cr with a PAT of ₹60cr, driven by European acquisitions despite slower domestic molecular diagnostic growth.
3B BlackBio Dx delivered strong consolidated growth in FY26, driven by the acquisition of Coris BioConcept. Strategy focuses on expanding the Molecular Diagnostics (MDx) portfolio and international market penetration.
3B BlackBio Dx Ltd reported revenue from operations of ₹35.4 Cr (+57.3% YoY) and net profit of ₹9.8 Cr (+22.5% YoY) for Q4 FY26.
3B BlackBio Dx reported FY2026 financial results and recommended a Rs. 5.00 per share dividend. The company also appointed M/s Ali Jain & Sharma as internal auditors.
3B BlackBio Dx Ltd paid a ₹0.02 Crore fine to BSE for board composition non-compliance. The company is now fully compliant with regulatory governance standards.
3B BlackBio Dx scheduled a board meeting for May 29, 2026. Directors will approve FY26 audited financial results and discuss a potential dividend recommendation.
3B BlackBio Dx Limited received approval for its equity shares to be admitted for trading on the National Stock Exchange under the 'Permitted to Trade' category. Trading is effective from April 20, 2026, enhancing the company's market visibility and liquidity.
3B BlackBio Dx Ltd submitted a confirmation regarding its non-applicability as a Large Corporate for FY 2021-2022. The company reported zero incremental borrowing and zero mandatory borrowing through debt securities. This compliance disclosure follows SEBI's framework for debt raising requirements.
3B BlackBio Dx Ltd submitted a declaration confirming it does not fall under the 'Large Corporate' category as per SEBI criteria. The company reported zero outstanding borrowings as of March 31, 2026. This regulatory filing ensures compliance with SEBI's debt disclosure framework.
3B BlackBio Dx Ltd submitted a yearly disclosure under SEBI SAST Regulations for FY 2025-26. Promoter Nikhil Kuber Dubey, on behalf of the promoter group, declared that no shares were encumbered or pledged directly or indirectly during the financial year ended March 31, 2026.